image credit: Vecteezy

Pfizer and Acuitas Therapeutics Collaborate on Lipid Nanoparticle Delivery System

January 11, 2022

Pfizer and Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems to enable messenger RNA (mRNA)-based therapeutics, have entered into a development and option agreement under which Pfizer will have the option to license, on a non-exclusive basis, Acuitas’ LNP technology for up to 10 targets for vaccine or therapeutic development, the companies announced in a Jan. 10, 2022 press release. Acuitas’ clinically-validated LNP technology is used in COMIRNATY, the Pfizer-BioNTech COVID-19 vaccine.

Read More on Biopharm International